medigraphic.com
ISSN 2448-8011 (Electronic)
Revista de Divulgación del INSTITUTO DE MEDICINA FORENSE de la UNIVERSIDAD VERACRUZANA

2017, Number 2

<< Back Next >>

Rev Mex Med Forense 2017; 2 (2)

ELISA method for the determination of Helicobacter pylori in samples of serum and saliva

Quijano GIA, Aguirre GÁA, Denis RPB, Parra UCL, Barrientos SC

Language: Spanish
References: 79
Page: 36-50
PDF size: 583.77 Kb.


ABSTRACT

Introduction: Helicobacter pylori has recently been associated with the etiology of acute gastritis, chronic gastritis, peptic ulcer, gastric adenocarcinoma and gastric lymphoma; traditional detection methods are invasive; therefore, it is important to evaluate non-invasive techniques for detection on accessible substrates such as serum and saliva.
Methods: Serum and saliva samples were collected from a population of 65 individuals aged 18-31 years, 71% female; the samples were analyzed by the IBL International ELISA kit; results were compared for sensitivity and specificity determinations.
Results: The results of the first 22 samples of serum and saliva were positive for both biological matrices, giving us a statistically significant association. When evaluating the results of the last 43 samples of serum and saliva we found some variability, without statistical significance.
Conclusion: The IgG ELISA kit is a sensitive method; taking into account the advantages for obtaining the samples of saliva and serum, this method can be considered as an aid for the non-invasive detection of H. pylori.


REFERENCES

  1. Arbelaez P, Maire M, Fowlkes C (2009). From Contours to Regions: An Empirical Evaluation. In CVPR.

  2. Alvarado J, Otero W, Archiva P (2007). Gastroenterologia y hepatología. Celsus, 533-539.

  3. Amieva MR, El-Omar EM, (2008). Host bacterial interactions infection. Gastroenterology, 134: 306 – 23.

  4. Asaka M, Takeda H, Sugiyama T (1997). What role does Helicobacter pylori play in gastric cancer? Gastroenterology; 113 (6); S56-S60.

  5. Bermejo F, Boixeda D, Gisbert P (2000). Eficacia de cuatro técnicas de amplio uso para el diagnóstico de la infección por Helicobacter pylori en la enfermedad ulcerosa gástrica. Rev Clin Esp; 20 (9): 475-479.

  6. Bermúdez L, Torres L, Rodríguez B (2009). Techniques used for the Helicobacter pylori infection detection. Journal Revista Cubana de Medicina, 48: 1.

  7. Boschian, CP (2012). Helicobacter pylori: Rol del agua y los alimentos en su transmisión. Anales venezolanos de nutricion-Scielo, 25 (2).

  8. Blaser, MJ (1992). Hypotheses on the pathogenesis and natural history of Helicobacter pylori-induced inflammation. Gastronterology 102:720-727.

  9. Buckley, MJ, O´Shea J, Grace A (1998). A community-based study of the epidemiology of Helicobacter pylori infection and associated asymptomatic gastroduodenal pathology. Eur J Gastroenterol Hepatol; 10 (5): 375-379.

  10. Cárdenas VM, Domínguez DC, Puentes FA (2008). Evaluation of a novel stool native catalase antigen test for Helicobacter pylori infection in asymptomatic North American children. J Pediatr Gastroenterol Nutr, 46:399-402.

  11. Camargo CP, Boschian ET (2012). Helicobacter pylori: Rol del agua y los alimentos en su transmisión. Anales Venezolanos de Nutrición Scielo , 25 (2), 85.

  12. Cavalier T (2002). The neomuran origin of archaebacteria, the negibacterial root of the universal tree and bacterial megaclassification. Int J Syst Evol Microbiol, 52: 7 – 76.

  13. Chomvarin C, Kulsantiwong P, Chantarasuk Y (2006). Comparison of media and antibiotic supplements for isolation of Helicobacter pylori from gastric biopsies. Southeast Asian J Trop Med Public Health, 37:1163-1169.

  14. Constanza CM, Lazcano PE, Torres J (2004). Determinants of Helicobacter pylori seroprevalence in Mexican adolescents Helicobacter; 9: 106 – 14.

  15. Cover, TL (1997). Commentary: Helicobacter pylori transmission, host factors, and bacterial factors. Gastroenterology; 113 (suppl 1): S29-S30.

  16. Clayton C, Kleanthous K, Tabaqchali S, (1991). Detection and identification of Helicobacter pylori by the polymerase chain reaction. J Clin Pathol, 44:515-516.

  17. Dowsett SA, Archiva L, Segret VA (1999). Helicobacter Pylori infection in indigenous families of Centra America: Serastatus and Oral Finger nail Carriage.J. Clin Microbiol, 37: 2456-2460.

  18. Ernst PB, Peura DA, Crowe SE (2006). The translation of Helicobacter pylori basic research to patient care. Gastroenterology; 130 (1): 188-206.

  19. Fawcett PT, Vinette KM, Gibney KM (2004). Comparison of PCR and clinical laboratory tests for diagnosing H. pylori infection in pediatric patients. BMC Microbiol, 4:5-10.

  20. Feu F (1998). Helicobacter pylori y linfoma gástrico tipo MALT: ¿erradicar la infección es suficiente? Gastroenterol Hepatol; 21 (supl 1): 40-44.

  21. Forné M (2001). Úlcera duodenal y Helicobacter pylori. En: Boixeda de Miquel, D., Martín de Argila, C., editores. Infección por Helicobacter pylori ¿más allá del límite?. Vol 1. 2ª ed. Barcelona: Prous Science; p. 177-192.

  22. Gisbert JP, Boixeda D, Martín C (1995). Infección por Helicobacterpylori y úlcera péptica. Gastroenterol Hepatol; 18 (supl 2): 44-52.

  23. Gisbert JP (2000). Revisión crítica de los métodos diagnósticos de infección por Helicobacter pylori. Gastroenterol Hepatol; 23: 135-143.

  24. Gisbert JP (2005a). Prevención de la recidiva hemorrágica por úlcera péptica mediante la erradicación de Helicobacter pylori. Gastroenterol Hepatol; 28 (9): 567-575.

  25. Goodwin CS, Armstrong JA, Chilvers T (1989). Transfer of Campylobacter pylori and Campylobacter mustelae to Helicobacter gen. nov. as Helicobacter pylori comb. Nov. and Helicobacter mustelae com. Noc., respectively. Ins Syst Bacteriol, 39: 397.

  26. Go MF (2002). Review article: natural history and epidemiology of Helicobacter pylori infection. Aliment Pharmacol Ther, 16 (Suppl 1):3-15.

  27. Graham DY, Smith JL, (1988). Gastroduodenal complications of chronic NSAID therapy. Am J Gastroenterol, 83: 1081-1084.

  28. Gutiérrez B, Vidal T, Valmaña CE (2005). Helicobacter pylori infection in Havana, Cuba. Prevalence and cagA status of the strains. VacciMonitor, 2:15-19.

  29. Hoang TT, Bengtsson C, Phung DC (2005). Seroprevalence of Helicobacter pylori infection in urban and rural Vietnam. Clin Diagn Lab Immunol; 12 (1): 81-85.

  30. Hofman LF (2001). Human saliva as a diagnostic specimen. J Nutr;131:1621S-25S.

  31. Houghton J, Stoicov C, Nomura S (2004). Gastric cancer originating from bone marrow derived cells. Science; 306: 1568-1571.

  32. Houghton J, Wang TC (2005). Helicobacter pylori and gastric cancer: a new paradigm for inflammation-asociated epithelial cancers. Gastroenterology; 128 (6):1567-1578.

  33. Isaacson PG, Wright DH (1983). Malignant lymphoma of mucosa-associated lymphoid tissue. A distinctive type of B-cell lymphoma. Cancer; 52: 1410-1416.

  34. Kignel S, de Almeida P, André EA (2005). Occurrence of Helicobacter pylori in dental plaque and saliva of dyspeptic patients. Oral Dis, 11:17-21.

  35. Krabis S (2004). Detection of Helicobacter pylori DNA in feces and saliva by Polimerase chain reaction: a review, 9:115-23.

  36. Lagunes YB (2001).Prevalencia de Helicobacter pylori en niños en edad escolar Rev Mex Patol Clin; 48: 23 – 26.

  37. Lee SG, Kim C, Chul HY (1997). Successful cultivation of a potential pathogenic coccoid organim with trophism for gastric mucin. Infect

  38. Lottspeich C, Schwarzer A, Panthel K (2007). Evaluation of the Novel H. pylori ClariRes Real-Time PCR Assay for Detection and Clarithromycin Susceptibility Testing of Helicobacter pylori in Stool Specimens from Symptomatic Children. J Clin Microbiol, 45(6):1718-22.

  39. Lu JJ, Perng CL, Shyu RY (1999). Comparison of five PCR methods for detection of Helicobacter pylori DNA in gastric tissues. J Clin Microbiol, 37:772-4.

  40. Madinier IM, Fosse TM, Monteil RA (1997). Oral carriage of Helicobacter pylori a review. Journal of Periodontology, 68(1):2-6.

  41. Malfertheiner P, Megraud F, O´Morain C. The European Helicobacter Pylori Study Group (2002). Current concepts in the management of Helicobacter pylori infection-The Maastricht 2-2000 Consensus Report. Aliment Pharmacol Ther; 16 (2): 167-180.

  42. Malfertheiner P, Sipponen P, Nauman M (2005). H. pylori erradication has the potencial to prevent gastric cancer: a State-of-the-Art Critique. Am J Gastroenterol; 100 (9): 2100-2114.

  43. Malfertheiner P, Megraud F, O´Morain C (2007). Current concepts in the management of Helicobacter pylori infection-The Maastricht III-2000 Consensus Report. Gut online: 17-01 (10.1136/gut.2006.101634).

  44. Manson JD, Eley BM (1993). O meio bucal na saude e na doenca. En: Manual de Periodontia. Sao Paulo, 165.

  45. Marshall B, Goodwin C (1987). Revised nomenclature of Campylobacter pyloridis. Inf J Syst Bacteriol, 37: 68.

  46. Marshall B, Warren R (1984). Unidentified curved bacilli in the stomach of patients with gastritis and peptic ulceration. Lancet, 16:1311-1315.

  47. Martín C, Boixeda D (2001). Consideraciones prácticas para el diagnóstico de la infección por Helicobacter pylori. Med Clin; 117: 386-391.

  48. Martín C, Boixeda D (2004). Helicobacter pylori y enfermedades relacionadas. Epidemiología y factores de riesgo. GH continuada; 3 (6): 251-255.

  49. Medina M, Gorodner L (2005). Evaluación del riesgo de infección por Helicobacter pylori en la práctica odontológica. Universidad del Nacional del Nordeste. Comunicaciones Científicas y Tecnológicas, M-018.

  50. Mégraud F (1995). Diagnosis of Helicobacter pylori. Clin Gastroenterology, 9: 507 – 18.

  51. Megraud F, Lehours P (2007). Helicobacter pylori Detection and Antimicrobial Susceptibility Testing. Clin Microbiol Rev, 20:280-322.

  52. Mohar A, Ley C, Guarner J (2002). Alta frecuencia de lesiones precursoras de cáncer gástrico asociado a Helicobacter pylori y respuesta al tratamiento en Chiapas, México Gac Med Mex; 138: 405 – 10.

  53. Monés J, Gisbert JP, Borda, F (2005). Indicaciones, métodos diagnósticos y tratamiento erradicador de Helicobacter pylori. Recomendaciones de la II Conferencia Española de Consenso. Rev Esp Enferm Dig; 97 (5): 348-374.

  54. Montalbán C, Santon A, Redondo C (2005). Long-term persistence of molecular disease after histological remission in low-grade gastric MALT lymphoma treated with H. pylori eradication. Lack of association with translocation t (11;18): a 10 year updated follow-up of a prospective study. Ann Oncology; 16 (9): 1539-1544.

  55. Nauntofte B, Tenevuo JO, Lagerlöf F (2003). Secretion and composition of saliva. In: Fejerskov O and Kidd E, eds. Dental Caries. The disease and its clinical management. Oxford. Blackwell Munksgard; p. 7-29.

  56. Pajares JM (2002). Infección por Helicobacter pylori. Rev Clin Esp; 202 (2): 99-110.

  57. Palli D, Masala G, Plebani M (2007). CagA+ Helicobacter pylori infection and gastric cancer risk in the EPICEURGAST study. Int J Cancer; 120 (4): 859-867.

  58. Quintero E, Menacho M (2004). Helicobacter pylori y enfermedades relacionadas. Relación con la gastritis y la úlcera péptica. GH continuada; 3 (6): 20-24.

  59. Raica M, Grigoras AM, Miutescu GE (1996). Clinical value of Helicobacter pylori identification by histochemical methods in patients with chronic gastritis. Rom J Morphol Embryol, 42:117-21.

  60. Rico J (2006). El Nobel de Medicina 2005 a Warren y Marshall,

  61. descubridores de Helicobacter pylori. Investig Clín; 9 (1): 78-80.

  62. Rodríguez CR, Alcántara LJJ, Lagunes YB (2006). Prevalencia del Helicobacter pylori en tres poblaciones de niños, de la ciudad de Puebla, México, y sus factores de riesgo Rev Gastroenterol Mex; 71 ( 4 ): 440 – 5.

  63. Sabbi T, De Angelis P, Colistro F (2005). Efficacy of noninvasive tests in the diagnosis of Helicobacter pylori infection in pediatric patients. Arch Pediatr Adolesc Med, 159:238-41.

  64. Sáinz S (1995). Infección por Helicobacter pylori y cáncer gástrico. Gastroenterol Hepatol; 18 (supl 2): 53-57.

  65. Sainz R, Borda F, Domínguez E (1999). Conferencia española de consenso sobre la infección por Helicobacter pylori. Rev Esp Enf Dig; 91 (11): 777-784.

  66. Sahay P, Axon AT (1996). Reservoirs of Helicobacter pylori and modes of transmission. Helicobacter; 1 (3): 175-182.

  67. Sierra F (2013). Tratamiento ideal del Helicobacter pylori: una revisión sistemática. Revista de Gastroenterología de México Elsevie, 22.

  68. Smoot DT (1997). How does Helicobacter pylori cause mucosal damage? Direct mechanisms. Gastroenterology; 113 (6); S31-S34.

  69. Sonmezoglu M, Baysal B, Ergen A (2005). Detection and evaluation of salivary antibodies to Helicobacter pylori in dyspeptic patients. Int J Clin Pract; 59: 433-436.

  70. Stolte M, Morgner A, Alpen A (2000). Evaluation of the long-term outcome of Helicobacter pylorirelated gastric mucosa-associated lymphoid tissue (MALT) lymphoma. En: Hunt, R.H., Tytgat, G.N.J., editores. p. 541-548.

  71. Tenovuo JO (1997). Salivary parameters of relevance for assesSing caries activity in individuals and populations. Comm Dent Oral Epidemiol, 25:82-6.

  72. Thiede C, Morgner A, Alpen B (1997). What role does Helicobacter pylori eradication play in gastric MALT and gastric MALT lymphoma? Gastroenterology; 113 (6): S61-64.

  73. Torres F (2007). El Ejercicio Actual de la Medicina. seminario el ejercicio actual de la medicina del Helicobacter pylori. España.

  74. Torres J, Leal HY, Pérez-Pérez. (1998). A community-based sero epidemiological study of Helicobacter pylori infection in México J Infect Dis; 178: 1089 94.

  75. Trakarnvanich V (2007). Methylene blue staining of gastric tissue for the identification of Helicobacter pylori. South Asian J Trop Med Public Health, 38:78-81.

  76. Vaira D, Holton J, Menegatti M (1999). New immunological assays for the diagnosis of Helicobacter pylori infection. Gut; 45 (suppl 1): I23-I27.

  77. Van Amsterdam K, van Vliet AH (2006). Of microbe and man: determinants of Helicobacter pylori-related diseases. FEMS Microbiol Rev; 30 (1): 131-156.

  78. Warren JR, Marshall B (1983). Unidentified curved bacilli on gastric epithelium inactive chronic gastritis. Lancet, 1273 – 75.

  79. Wotherspoon AC, Ortiz-Hidalgo C, Falzon MR (1991). Helicobacter pylori associated gastritis and primary B-cell lymphoma. The Lancet; 338: 1175-1176.




2020     |     www.medigraphic.com